Fig. 1From: A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocolNEJ045A Study Design. Abbreviations: ES-SCLC, extensive-stage small-cell lung cancer; ECOG, Eastern Cooperative Oncology Group; PS, performance status; AUC, area under the curve; PD, progressive diseaseBack to article page